Department of Defense Serum Repository

Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Wednesday, November 8, 2023

Phase 1 clinical trial, last patient last visit occurred in September, data lock achieved on November 1, 2023 and top-line results are expected in December 2023 with full study report to follow.

Key Points: 
  • Phase 1 clinical trial, last patient last visit occurred in September, data lock achieved on November 1, 2023 and top-line results are expected in December 2023 with full study report to follow.
  • Interim phase 1 clinical trial safety results are helping to accelerate the adoption of our C1 protein production platform in use for manufacturing human vaccines.
  • In October 2023, the Company received an upfront payment of $0.6 million for product development.
  • The Company is making progress in developing animal-free recombinant serum albumin with initial positive analytical results towards commercialization and prospective licensing opportunities.

Toney Healthcare Expands Insource Partnership with St. Vincent Catholic Medical Centers US Family Health Plan, Enhancing Support for 13,000+ TRICARE Prime Beneficiaries

Retrieved on: 
Tuesday, November 7, 2023

TAMPA, Fla., Nov. 7, 2023 /PRNewswire/ -- Toney Healthcare today announced that it has extended its partnership with St. Vincent Catholic Medical Centers Uniformed Services Family Health Plan (USFHP) to include the entire process of medical utilization management. USFHP supports approximately 13,000 beneficiaries of the Department of Defense-sponsored TRICARE Prime program located in New York, New Jersey, Pennsylvania and Connecticut. TRICARE Prime is available to military families and retirees.

Key Points: 
  • TAMPA, Fla., Nov. 7, 2023 /PRNewswire/ -- Toney Healthcare today announced that it has extended its partnership with St. Vincent Catholic Medical Centers Uniformed Services Family Health Plan (USFHP) to include the entire process of medical utilization management.
  • USFHP supports approximately 13,000 beneficiaries of the Department of Defense-sponsored TRICARE Prime program located in New York, New Jersey, Pennsylvania and Connecticut.
  • Toney Healthcare is also working closely with USFHP on technology transitions that will further enable the health plan to better support its members and provider community.
  • "The Toney Healthcare team consistently exceeds our expectations in delivering high-quality, timely, clinically correct decision-making to support our members and providers."

Stupid Strong Charitable Foundation Pledges $450,000 Grant to Advance Gastric Cancer Family Study

Retrieved on: 
Wednesday, November 1, 2023

This grant will propel the "Cancer Patients' Family Matters" study led by Dr. Jaffer Ajani, aimed at unraveling the mysteries behind the hereditary nature of gastric cancer and developing strategies for early detection and prevention.

Key Points: 
  • This grant will propel the "Cancer Patients' Family Matters" study led by Dr. Jaffer Ajani, aimed at unraveling the mysteries behind the hereditary nature of gastric cancer and developing strategies for early detection and prevention.
  • The research, supported by Stupid Strong, will focus on enrolling gastric cancer patients and their family members, totaling 500 patients and 5,000 individuals overall.
  • This generous grant from the Stupid Strong Charitable Foundation will enable Dr. Ajani to hire staff, identify study participants, administer detailed lifestyle questionnaires, and collect and process blood samples.
  • For more information about the Stupid Strong Charitable Foundation, please visit www.stupidstrong.org .

U.S. Defense Health Agency selects Amwell® and Leidos to power the Digital First initiative for the U.S. Military Health System

Retrieved on: 
Thursday, October 19, 2023

Under this task order, the Leidos Partnership for Defense Health (LPDH) will deliver Amwell Converge™, a comprehensive hybrid care enablement platform designed to power the full continuum of care using digital, virtual and automated modalities, and replace the Military Health System (MHS) Video Connect solution.

Key Points: 
  • Under this task order, the Leidos Partnership for Defense Health (LPDH) will deliver Amwell Converge™, a comprehensive hybrid care enablement platform designed to power the full continuum of care using digital, virtual and automated modalities, and replace the Military Health System (MHS) Video Connect solution.
  • “Through our world class platform Converge, Amwell is already enabling hybrid care across the commercial marketplace.
  • The DHA’s Digital First initiative brings new capabilities and enablement to MHS GENESIS , an advanced electronic health record (EHR) and healthcare system solution that supports military and Veteran healthcare initiatives.
  • “Digital First addresses DHA’s goal of better outcomes, new processes, innovation and increased standardization based on evidence,” said Jason McCarthy, Leidos senior vice president, Military and Veterans Health Solutions.

Leidos Awarded $180M Defense Health Agency Virtual Health Task Order

Retrieved on: 
Thursday, October 19, 2023

RESTON, Va., Oct. 19, 2023 /PRNewswire/ -- Leidos (NYSE:LDOS), a FORTUNE® 500 science and technology leader, was recently awarded a next-generation contract to provide the Defense Health Agency (DHA) with new virtual health capabilities for providers and patients.

Key Points: 
  • RESTON, Va., Oct. 19, 2023 /PRNewswire/ -- Leidos (NYSE:LDOS), a FORTUNE® 500 science and technology leader, was recently awarded a next-generation contract to provide the Defense Health Agency (DHA) with new virtual health capabilities for providers and patients.
  • The hybrid CPIF/FFP task order was awarded by DHA's Program Executive Office Defense Healthcare Management Systems (PEO DHMS).
  • If all options are exercised, the task order has a 22-month period of performance with a total value of $180 million.
  • Under the contract, the Leidos Partnership for Defense Health (LPDH) will replace the Military Health System (MHS) Video Connect solution with Amwell's Converge™ platform.

Retired USMC Sgt. Jonathan Lubecky joins Veterans Exploring Treatment Solutions (VETS) as Legislative Director, Underscoring Commitment to Reform

Retrieved on: 
Wednesday, October 18, 2023

WASHINGTON , Oct. 18, 2023 /PRNewswire-PRWeb/ -- Veterans Exploring Treatment Solutions (VETS), a leading non-profit organization dedicated to ending veteran suicide, today announced the appointment of retired USMC Sgt. Jonathan Lubecky as Legislative Director to lead VETS' policy reform and advocacy efforts.

Key Points: 
  • Jonathan Lubecky as Legislative Director to lead VETS' policy reform and advocacy efforts.
  • Jonathan's appointment to Legislative Director underscores VETS' commitment to furthering these efforts.
  • Jonathan Lubecky said, "Joining VETS in its mission to bridge the gap in veterans' access to life-saving mental health care is an honor.
  • For more information or to become a sponsor, please visit vetsolutions.org/gala or download the Sponsorship Brochure .

Leidos Partnership Deploys MHS GENESIS Overseas in First of Two Planned OCONUS Waves

Retrieved on: 
Tuesday, October 17, 2023

RESTON, Va., Oct. 17, 2023 /PRNewswire/ -- The Leidos Partnership for Defense Health (LPDH) today announced it successfully delivered the MHS GENESIS electronic health record to an additional 9,000 Department of Defense (DOD) clinicians and providers as part of its first Outside of the Contiguous United States (OCONUS) deployment (Waves LANDSTUHL/LAKENHEATH). The current system deployment spans 10 Military Treatment Facilities (MTFs) across Europe and the United Kingdom. Additionally, LPDH deployed MHS GENESIS to users at Fort Buchanan, Puerto Rico and Guantanamo Bay, Cuba.

Key Points: 
  • Additionally, LPDH deployed MHS GENESIS to users at Fort Buchanan, Puerto Rico and Guantanamo Bay, Cuba.
  • With this latest overseas DOD wave deployment, the MHS GENESIS system is now operational at over 3,500 locations and now reaches over seven million DOD beneficiaries.
  • MHS GENESIS is 91% deployed to DOD garrison facilities and will next deploy to Far East locations in October 2023.
  • MHS GENESIS is being deployed across the continental United States and overseas through a total of 23 waves, with each wave targeting a specific region.

Vistant Selected To Support Defense Health Agency’s National Capital Region Logistics Program

Retrieved on: 
Thursday, October 12, 2023

Vistant will provide program management support for DHA’s National Capital Region (NCR) Medical Directorate Logistics & Acquisition Support Program.

Key Points: 
  • Vistant will provide program management support for DHA’s National Capital Region (NCR) Medical Directorate Logistics & Acquisition Support Program.
  • Under this two-year, $3.7 million project, Vistant will staff, manage, and operate logistics for the NCR from the Walter Reed National Military Medical Center annex.
  • Earlier this year, Vistant was awarded a contract to provide operational support through DHA’s Clinical Operations Program Management Office.
  • Vistant paralegal experts now support active duty and retired service members of the Army, Navy, Air Force, Marines, Coast Guard, Public Health Service, and their dependents, as well as civilian employees of the Department of Defense.

FDA Grants ExThera Multiple Breakthrough Device Designations for its Seraph® 100 Filter

Retrieved on: 
Tuesday, October 3, 2023

ExThera Medical Corporation, a healthcare company developing and manufacturing extracorporeal pathogen technologies, announces that it has received multiple Breakthrough Device Designations from the U.S. Food and Drug Administration (FDA), for its Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100).

Key Points: 
  • ExThera Medical Corporation, a healthcare company developing and manufacturing extracorporeal pathogen technologies, announces that it has received multiple Breakthrough Device Designations from the U.S. Food and Drug Administration (FDA), for its Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100).
  • The Seraph 100 is a patented blood filter containing a biomimetic surface, similar to that found in the human circulatory system that removes pathogens that could otherwise overwhelm a patient; a common source of severe/critical illness.
  • “In addition, a Breakthrough Device Designation allows for immediate coverage through Centers for Medicare and Medicaid Services (CMS) via New Technology Add-On Payment (NTAP).
  • Breakthrough Device Designations are an important addition to this ongoing activity, along with future pandemic preparedness.

GateHouse Treatment Appoints New CEO

Retrieved on: 
Thursday, September 28, 2023

NASHUA, N.H., Sept. 28, 2023 /PRNewswire/ -- GateHouse Treatment, a premier addiction and behavioral health service provider, proudly welcomes Theodore Bender, PhD, MBA, as its new Chief Executive Officer (CEO). Dr. Bender's exceptional background in clinical psychology, distinguished education, and remarkable track record in executive leadership make him the ideal leader for GateHouse Treatment.

Key Points: 
  • NASHUA, N.H., Sept. 28, 2023 /PRNewswire/ -- GateHouse Treatment, a premier addiction and behavioral health service provider, proudly welcomes Theodore Bender, PhD, MBA, as its new Chief Executive Officer (CEO).
  • Dr. Bender's exceptional background in clinical psychology, distinguished education, and remarkable track record in executive leadership make him the ideal leader for GateHouse Treatment.
  • As CEO of GateHouse, Dr. Bender spearheads the mission of providing top-tier addiction & behavioral health services.
  • As CEO of GateHouse, Dr. Bender spearheads the mission of providing top-tier addiction & behavioral health services.